Peptides

A synthetic peptide for use as a blocking control in assays to test for specificity of TAPBP antibody, catalog no. 70R-6000

A synthetic peptide for use as a blocking control in assays to test for specificity of MTHFS antibody, catalog no. 70R-3776

A synthetic peptide for use as a blocking control in assays to test for specificity of ERCC4 antibody, catalog no. 70R-2117

A synthetic peptide for use as a blocking control in assays to test for specificity of SFRS2 antibody, catalog no. 70R-10293

Insulin is a hormone that regulates the metabolism of carbohydrates and fats. It is produced by beta cells in the pancreas and prevents hyperglycemia. Insulin binds to insulin-specific receptors on the cell membrane, resulting in increased glucose uptake by muscle and fat cells. Monoclonal Mouse Anti-Human Insulin is an antibody that binds to human insulin and blocks its action, thereby lowering blood sugar levels. This antibody was immunised with human insulin and purified from mouse spleen cells. The antibody has been shown to block glycogen synthesis and fatty acid synthesis in vitro. Monoclonal Mouse Anti-Human Insulin also has a high binding affinity for erythrocytes and penetrates these cells easily. When injected into humans, this antibody binds to the erythrocytes in the blood stream and prevents their passage through capillary walls into tissues such as muscle or fat cells, thereby preventing glycolysis (the conversion of glucose into energy) in those tissues

A synthetic peptide for use as a blocking control in assays to test for specificity of EIF3H antibody, catalog no. 70R-8910

A synthetic peptide for use as a blocking control in assays to test for specificity of ANKRD39 antibody, catalog no. 70R-9456

A synthetic peptide for use as a blocking control in assays to test for specificity of HABP2 antibody, catalog no. 70R-6071

A synthetic peptide for use as a blocking control in assays to test for specificity of MFN1 antibody, catalog no. 70R-4467

A synthetic peptide for use as a blocking control in assays to test for specificity of Sin3b antibody, catalog no. 70R-8194

A synthetic peptide for use as a blocking control in assays to test for specificity of QARS antibody, catalog no. 70R-9414

A synthetic peptide for use as a blocking control in assays to test for specificity of PNMA2 antibody, catalog no. 70R-9173

A synthetic peptide for use as a blocking control in assays to test for specificity of XTP3TPA antibody, catalog no. 70R-3772

A synthetic peptide for use as a blocking control in assays to test for specificity of PYHIN1 antibody, catalog no. 70R-9020

Sarafotoxin S6b, sourced from the venom of the Atractaspis engaddensis snake family, is one of four (S6a-d) isopeptides of the Sarafotoxins. This product is a synthetically produced toxin, containing disulfide bonds between Cys1-Cys15 and Cys3-Cys11.Due to their structural and functional homology to the endothelin peptides, Sarafotoxins can enhance vasoconstriction through stimulating the class A G-protein-coupled, endothelin ETA and ETB receptors. This in turn leads to left ventricular dysfunction and bronchoconstriction.
As the most potent Sarafotoxin, sarafotoxin S6b binds to both ETA and ETB receptors with a similar affinity to Endothelin-1. This is evident as when given to mice intravenously, sarafotoxin S6b caused cardiac arrest and death in mice almost immediately. Additional characteristics of S6b is its matrix metalloproteinase inhibitory activity due to it exhibiting a fold which is also found in the core region of tissue inhibitors of metalloproteinases (TIMPs).
Sarafotoxin S6b can be used as a pharmacological reagent to study the interactions of Endothelins and their corresponding receptors. This product is available as a 0.1mg vial.

A synthetic peptide for use as a blocking control in assays to test for specificity of DNAJC10 antibody, catalog no. 70R-6576

A synthetic peptide for use as a blocking control in assays to test for specificity of DPH2 antibody, catalog no. 70R-3392

Custom research peptide; min purity 95%.

Light chain of the bevacizumab monoclonal antibody, sold as the antitumour therapeutic Avastin. It prevents vascular endothelial growth factor (VEGF) from binding to VEGF receptors 1 and 2 thus inhibiting angiogenesis in tumours.

A synthetic peptide for use as a blocking control in assays to test for specificity of COPA antibody, catalog no. 70R-6205

A synthetic peptide for use as a blocking control in assays to test for specificity of POLD2 antibody, catalog no. 70R-5521

A synthetic peptide for use as a blocking control in assays to test for specificity of TTC5 antibody, catalog no. 70R-2121

A synthetic peptide for use as a blocking control in assays to test for specificity of PIGT antibody, catalog no. 70R-7466

Motilin is a peptide that is used as a research tool in the fields of cell biology, pharmacology, and biochemistry. It is an activator of the motilin receptor and has been shown to bind to ligand-gated ion channels. Motilin has also been shown to inhibit the activity of high-voltage activated calcium channels.

A synthetic peptide for use as a blocking control in assays to test for specificity of ARL17 antibody, catalog no. 70R-3805

A synthetic peptide for use as a blocking control in assays to test for specificity of ZDHHC21 antibody, catalog no. 70R-4550

A synthetic peptide for use as a blocking control in assays to test for specificity of AKR1C1 antibody, catalog no. 70R-10003

A synthetic peptide for use as a blocking control in assays to test for specificity of ARHGAP28 antibody, catalog no. 70R-3943

AMY1A is a tryptic peptide derived from the alpha-amylase 1 from the salivary gland of the fruit fly, Drosophila melanogaster. Alpha-amylase 1 is a member of the amylase family and has been shown to be biologically active in vitro. AMY1A is used as a calibrator for mass spectrometry and proteomics applications. It is also used in conjunction with other peptides to identify proteins in proteomic experiments.

A synthetic peptide for use as a blocking control in assays to test for specificity of FBLN1 antibody, catalog no. 70R-5356

A synthetic peptide for use as a blocking control in assays to test for specificity of HOXA5 antibody, catalog no. 70R-8341

A synthetic peptide for use as a blocking control in assays to test for specificity of HNF4A antibody, catalog no. 70R-2034

A synthetic peptide for use as a blocking control in assays to test for specificity of KLHDC8B antibody, catalog no. 70R-3775

A synthetic peptide for use as a blocking control in assays to test for specificity of ADAMTS18 antibody, catalog no. 70R-4602

A synthetic peptide for use as a blocking control in assays to test for specificity of DDX50 antibody, catalog no. 70R-1367

A synthetic peptide for use as a blocking control in assays to test for specificity of PCMT1 antibody, catalog no. 70R-1558

A synthetic peptide for use as a blocking control in assays to test for specificity of SPTAN1 antibody, catalog no. 70R-2207

α7 nAChR selective blocker

A synthetic peptide for use as a blocking control in assays to test for specificity of ZCCHC13 antibody, catalog no. 70R-4279

A synthetic peptide for use as a blocking control in assays to test for specificity of DFFA antibody, catalog no. 20R-1064

A synthetic peptide for use as a blocking control in assays to test for specificity of Vamp1 antibody, catalog no. 70R-9793

A synthetic peptide for use as a blocking control in assays to test for specificity of SCG3 antibody, catalog no. 70R-9777

A synthetic peptide for use as a blocking control in assays to test for specificity of SLC34A3 antibody, catalog no. 70R-7873

A synthetic peptide for use as a blocking control in assays to test for specificity of STK39 antibody, catalog no. 70R-1017

A synthetic peptide for use as a blocking control in assays to test for specificity of CLDN2 antibody, catalog no. 20R-1258

A synthetic peptide for use as a blocking control in assays to test for specificity of CSNK2A2 antibody, catalog no. 70R-3332

A synthetic peptide for use as a blocking control in assays to test for specificity of LIN7C antibody, catalog no. 70R-2196

A synthetic peptide for use as a blocking control in assays to test for specificity of FAM120C antibody, catalog no. 70R-10170

A synthetic peptide for use as a blocking control in assays to test for specificity of TPX2 antibody, catalog no. 70R-5626

A synthetic peptide for use as a blocking control in assays to test for specificity of CYP2R1 antibody, catalog no. 70R-8833

MAL-dPEG®4-(m-dPEG®4)3 is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. MAL-dPEG®4-(m-dPEG®4)3 is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Extraordinary strength of the streptavidin-biotin interaction allows for efficient capturing of even highly dilute targets; however, it makes recovery of proteins from affinity resins challenging. Conventional methods to elute biotinylated proteins from immobilized avidin include the following: (i) denaturation of streptavidin by boiling the resin in a denaturing buffer that may include high concentrations of chaotropic salts, (ii) trypsin digestion of proteins while they are bound to the resin, or (iii) elution of proteins with excess free biotin. These protocols can co-elute contaminant proteins by releasing nonspecifically bound proteins and/or naturally biotinylated proteins concurrently with labeled proteins. In addition, some of these methods can cause elution of high levels of resin-based peptides along with the proteins of interest, resulting in further sample contamination.
Disulfide Biotin Azide probe eliminates a major limitation of the streptavidin-biotin affinity purification. This reagent contains a biotin moiety linked to an azide moiety through a spacer arm containing a cleavable disulfide linker. Captured biomolecules can be efficiently released under mild conditions (50 mM dithiothreitol, 10 mM 2-mercaptoethanol or 1% sodium borohydride) and the small molecular fragment (188.25 Da) left on the labeled protein following cleavage. These features make the cleavable probe especially attractive for use in biomolecular labeling and proteomic studies.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Myelin oligodendrocyte glycoprotein (MOG) is a myelin protein found in the central nervous system. MOG is a ligand for CD200, which is an inhibitory receptor expressed by astrocytes. It has been shown that MOG can induce the proliferation and differentiation of primary cultures of rat astrocytes in vitro. MOG induces the production of reactive oxygen species in mitochondria and increases the expression of acid-binding protein, which are both important factors in the demyelination process. MOG has also been implicated as a potential factor in the development of multiple sclerosis. Further research into this protein may lead to new treatments or cures for disorders such as encephalomyelitis, nervous system diseases, or even cancer.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

CJC-1295 is a synthetic peptide, which is an analogue of growth hormone-releasing hormone (GHRH). It is synthesized through recombinant DNA technology, which allows for precise control over its sequence and length. This particular peptide is designed to bind to GHRH receptors in the pituitary gland. By activating these receptors, CJC-1295 stimulates the release of growth hormone (GH) into the bloodstream.The primary function of CJC-1295 is to influence the endocrine system, particularly enhancing the release of endogenous growth hormone. It achieves this by increasing the amplitude and frequency of GH pulses without affecting the natural negative feedback mechanisms that regulate GH production. This mode of action distinguishes CJC-1295 from other growth hormone therapies, as it promotes a more physiological pattern of hormone secretion.CJC-1295 is used in various scientific contexts, primarily in research focusing on growth hormone deficiencies, muscle wasting conditions, and certain metabolic disorders. Its ability to increase GH release also makes it a subject of interest in studies related to aging, tissue repair, and regeneration. The longer half-life of CJC-1295 compared to natural GHRH peptides further enhances its applications in research, allowing for more sustained and controlled experimentation.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Please enquire for more information about Fluorescein-6-carbonyl-Leu-Glu(OMe)-His-DL-Asp(OMe)-fluoromethylketone including the price, delivery time and more detailed product information at the technical inquiry form on this page

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

H-His-Arg-OH is a synthetic peptide that has been shown to have cytotoxic effects on mammalian cells. The H-His-Arg-OH peptide can be used for the treatment of heart disease and autoimmune diseases, such as rheumatoid arthritis. This peptide has been found to be resistant to congestive heart failure, which is caused by a number of factors, including hypertension and valvular stenosis. It has also been shown to have an immunoglobulin G1 (IgG1) genotype.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity